Somatropin Biopartners receives marketing authorisation in the EU, Norway and Iceland

The European Commission has granted a marketing authorisation to Somatropin Biopartners, a prolonged-release somatropin-containing medicinal product. Somatropin Biopartners allows for a once-weekly injection instead of the currently available therapies that require once-daily injections of growth hormone. Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current growth hormone replacement therapy in children as well as adults.